XORTX Therapeutics Inc. (XRTX) Stock Price & Analysis
XORTX Therapeutics Inc. (XRTX) — MoonshotScore 32/100 (Weak band), calculated Nov 18, 2026. Price $0.89 (-16.04%), as of the Nov 19, 2026 trading session; market cap $2.00M.
Educational signal · not a buy or sell recommendation · How to read this
XORTX Therapeutics Inc. · XRTX
XORTX Therapeutics Inc. is a bio-pharmaceutical company focused on developing and commercializing therapies for progressive kidney diseases, diabetes, and related complications.
Price as of Nov 19, 2026
Key Statistics
MoonshotScore v2 · XORTX Therapeutics (XRTX)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Weak quality and an expensive valuation, though the balance sheet and growth are only middling, and the price trend has turned against it. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone. Business Quality: Thin; Financial Safety: Okay; Valuation: Rich; Growth Durability: Flat; Momentum: Slipping.
Earnings yield is the main valuation drag relative to sector peers.
- EPS beat 6 of the last 8 reports
- Altman Z -5.97 · Piotroski F 1
Holding back: weak fundamentals, a rich price, weak price trend
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 30 | Weak | |
| 30 | Weak | |
| 34 | Weak | |
| 34 | Weak | |
| 32 | Weak | |
| 32 | Weak |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $0.89 | |
| Change on the day | -16.04% | |
| 52-week range | $0.83 – $3.60 | |
| Market capitalisation | $2.00M | — |
| Shares traded on the day | 51.1K |
Price & events
What is XORTX Therapeutics (XRTX), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. XORTX Therapeutics Inc. (XRTX) is the company analyzed here. It employs 2 people and is led by Allen Warren Davidoff. The market values it at $2.00M.
What do the latest results show for XORTX Therapeutics (XRTX)?
Short answer · as of
Against analyst estimates the company has EPS beat 6 of the last 8 reports.
What are the financial strengths and risks for XORTX Therapeutics (XRTX)?
Short answer · as of
What is holding it back is weak fundamentals, a rich price, weak price trend. The distress and quality screens read Altman Z -5.97 · Piotroski F 1. Trailing ratios: ROA -60.7% · current ratio 3.59.
Data-derived red flags
- Financial-distress signal — its Altman Z-Score of -5.97 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
What should you watch next at XORTX Therapeutics (XRTX)?
Short answer · as of
Analyst estimates on file carry FY2026 revenue $3.25M · EPS -1.75 · 1 analysts.
What the records here don't tell us
- The next earnings date is not yet scheduled in the calendar we read.
- No insider Form 4 transaction falls inside the window this page reads.
- No quarterly income statement is held for XRTX.
Checked against the records this page reads, on the dates shown above.
How does XORTX Therapeutics compare with its peers?
Short answer
XORTX Therapeutics's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $13.33 Nov 18, 2026 | $471M | 91 5-pillar Nov 18, 2026 | |
| $9.07 Nov 19, 2026 | $540M | 91 5-pillar Nov 18, 2026 | |
| $3.06 Nov 19, 2026 | $258M | 90 5-pillar Nov 18, 2026 | |
| $42.53 Nov 18, 2026 | $801M | 88 5-pillar Nov 18, 2026 | |
| $15.26 Nov 18, 2026 | $85.5M | 82 5-pillar Nov 18, 2026 | |
| $11.25 Nov 18, 2026 | $102M | 82 5-pillar Nov 18, 2026 | |
| $3.89 Nov 18, 2026 | $169M | 72 5-pillar Nov 18, 2026 | |
| $1.88 Nov 19, 2026 | $178M | 69 5-pillar Nov 18, 2026 | |
| $12.17 Nov 19, 2026 | $861M | 69 5-pillar Nov 18, 2026 | |
| $9.28 Nov 19, 2026 | $545M | 68 5-pillar Nov 18, 2026 | |
| $8.14 Nov 19, 2026 | $796M | 63 5-pillar Nov 18, 2026 | |
| $3.13 Nov 19, 2026 | $481M | 60 5-pillar Nov 18, 2026 | |
| XORTX Therapeutics (XRTX) — this page | $0.89 | $2.00M | 32 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Revenue estimate
- $3.25M
- EPS estimate
- $-1.75
Measured against a quoted price of $0.89 (as of Nov 19, 2026).
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held XRTX in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported XRTX in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
Investor Questions: XRTX Stock
These answers are editorial: 1 of these 9 answers is drawn from the XRTX research dossier (written Mar 17, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.
What does the MoonshotScore mean for XRTX?
XRTX carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.
Is XRTX a good stock to buy?
Stock Expert AI does not rate XRTX buy, sell or hold. XORTX Therapeutics Inc. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the XRTX stock price today?
The last price recorded for XORTX Therapeutics Inc. (XRTX), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What are the main risks for XRTX?
XORTX Therapeutics Inc. faces several key risks, including the potential for clinical trial failures, regulatory hurdles, and competition from larger pharmaceutical companies. Given its small size and limited resources, XORTX is particularly vulnerable to these risks.
What are the key factors to evaluate for XRTX?
XORTX Therapeutics Inc. (XRTX) holds a MoonshotScore in the low range. XORTX Therapeutics is focused on developing therapies for progressive kidney diseases, including autosomal dominant polycystic kidney disease (ADPKD). Not financial advice.
How frequently does XRTX data refresh on this page?
XRTX's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven XRTX's recent stock price performance?
XORTX Therapeutics Inc. (XRTX) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Focus on unmet needs in kidney disease. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider XRTX overvalued or undervalued right now?
XORTX Therapeutics Inc. (XRTX) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research XRTX before investing?
Before investing in XORTX Therapeutics Inc. (XRTX), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 17, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 16 figures on this page — 4 from Financial Modeling Prep (FMP), 10 with no recorded source and 2 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com